CAJ | 학술논문

目的：探讨唑来膦酸联合钙尔奇D治疗原发性骨质疏松症临床疗效及安全性。方法：唑来膦酸注射液4mg ，用0．9％氯化钠注射液或5％葡萄糖注射液100ml稀释后静脉滴注，滴注时间≥15min。同时口服钙尔奇D片600mg ，1次/d ，疗程为12个月。结果：本组43例患者经唑来膦酸联合钙尔奇D治疗6个月、12个月后骨痛症状明显改善，较治疗前骨痛NRS评分明显降低，差异有统计学意义（P＜0．05），腰椎L1～4与股骨颈骨密度（BMD）值，较治疗前有明显增长，差异有显著性（P＜0．05），而患者血钙（Ca）、血磷（P）检测值与治疗前比较无明显变化，差异无统计学意义（P＞0．05），骨形成标志物OC、BALP值下调，治疗后12个月两者测定接近于正常值，其中OC值治疗后12个月较治疗前下降明显，差异有统计学意义（P＜0．05）；而骨吸收标志物β-CTx、DPD/Cr比值，治疗后下降迅速，与治疗前比较，差异具有显著性（P＜0．05）。结论：唑来膦酸联合钙尔奇D治疗原发性OP可有效改善骨痛症状与骨代谢相关指标，增加骨量，不良反应少，患者依从性较好。
목적：탐토서래련산연합개이기D치료원발성골질소송증림상료효급안전성。방법：서래련산주사액4mg ，용0．9％록화납주사액혹5％포도당주사액100ml희석후정맥적주，적주시간≥15min。동시구복개이기D편600mg ，1차/d ，료정위12개월。결과：본조43례환자경서래련산연합개이기D치료6개월、12개월후골통증상명현개선，교치료전골통NRS평분명현강저，차이유통계학의의（P＜0．05），요추L1～4여고골경골밀도（BMD）치，교치료전유명현증장，차이유현저성（P＜0．05），이환자혈개（Ca）、혈린（P）검측치여치료전비교무명현변화，차이무통계학의의（P＞0．05），골형성표지물OC、BALP치하조，치료후12개월량자측정접근우정상치，기중OC치치료후12개월교치료전하강명현，차이유통계학의의（P＜0．05）；이골흡수표지물β-CTx、DPD/Cr비치，치료후하강신속，여치료전비교，차이구유현저성（P＜0．05）。결론：서래련산연합개이기D치료원발성OP가유효개선골통증상여골대사상관지표，증가골량，불량반응소，환자의종성교호。
Objective :To discuss zoledronate (ZOD) with Caltrate D in primary clinical efficacy and safety of osteopo-rosis .Methods :Zoledronate Acid Injection 4mg ,with 0 .9% sodium chloride injection or 5% glucose injection 100ml di-luted intravenous infusion ,at the same time oral Caltrate D 600mg ,1time/d ,period of treatment is 12 months .Results:This group of 43 patients treated by zoledronate (ZOD) joint Caltrate D treatment for 6 months ,12 months after the pain symptoms improved ,compared with those before treatment NRS pain scores decreased significantly ,the difference was statistically significant (P<0 .05) ,Lumbar L1~4 and femoral neck bone mineral density (BMD)numerical ,there are obviously increased compared with before treatment ,there were significant differences (P<0 .05) ,the serum calcium (Ca) ,phosphorus (P) detection value have no significant difference compared with before treatment ,the difference was not statistically significant (P>0 .05) ,bone formation markers OC ,BALP value reduced smooth ,after 12 months of treatment both measured close to normal ,the difference was statistically significant (P< 0 .05);bone resorption markers β-CTx ,DPD/Cr ratio ,and decreased after the treatment quickly ,compared with before treatment ,the differ-ence was significant (P<0 .05) .Conclusion:Zoledronate combined with Caltrate D treatment of primary osteoporosis can be effective in improving the symptoms of pain associated with bone metabolism indicators ,increase the bone mass , less adverse reaction ,patient compliance is good .